세계의 이식 면역억제제 시장 : 예측(2023-2028년)

The transplant immunosuppressive drugs market is expected to grow at a compound annual growth rate of 6.90% over the forecast period, reaching US$14.510 billion in 2028 from US$9.096 billion in 2021.

The market in recent times has been witnessing advancements in transplantation techniques, including minimally invasive procedures and improved post-transplant care, which have increased the success rates of organ transplants. This has led to a higher demand for transplant immunosuppressive drugs to maintain the viability of transplanted organs and prevent rejection.

These drugs help protect patients against rejection of the transplanted foreign organ by their bodies. Moreover, the rising prevalence of chronic diseases such as cardiovascular disease, diabetes, cancer, and asthma is expected to increase the demand for organ transplants, further boosting the transplant immunosuppressive drugs market during the forecast period.

Significant advancements in pharmaceutical research and development have led to the introduction of new and improved transplant immunosuppressive drugs. These drugs are designed to enhance efficacy, minimize side effects, and improve patient outcomes, driving market growth. Moreover, the aging population is more prone to organ failure and chronic diseases, leading to a higher demand for organ transplantation. As the geriatric population grows globally, the transplant immunosuppressive drugs market is expected to expand further.

One of the primary reasons driving the market's growth is the increased number of organ transplant surgeries.

According to the health resources and services administration, 42,000+ transplants were performed in 2022, out of which 25,499 were for kidneys, 9,528 were for the liver, 108 were for the pancreas, 4,111 were for the heart, and 2,692 were for others.

Advancements in surgical techniques have improved the success rates of organ transplant surgeries, making them safer and more viable treatment options. Minimally invasive procedures, laparoscopic techniques, and innovative transplant approaches, such as living donor transplants and paired organ exchange programs, have expanded the pool of available organs and increased the number of surgeries performed. Furthermore, governments, healthcare organizations, and non-profit organizations have established dedicated programs and networks to promote and facilitate organ transplantation. These initiatives focus on creating efficient organ allocation systems, improving transplantation infrastructure, and increasing awareness about organ donation. For example, the United Network for Organ Sharing (UNOS) in the United States manages the organ transplant system and helps coordinate the allocation of organs.

The organ transplantation segment will constitute a significant market share.

The transplant immunosuppressive drug market is segmented by transplant type into tissue and organ transplantation. According to the data collected by health resources and service administration on January 2023, there were 25,499 kidney transplants, whereas 9,528 liver transplants and heart and lung transplants were 4,111 and 2,692, respectively. Other transplants in the graph include allograft transplants like the face, hands, and abdominal wall.

The transplant immunosuppressive drugs market, by geography, is analyzed into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The development in tissue engineering and growing expenditure on healthcare, coupled with the increase in organ transplant surgeries, are driving the market growth for transplant immunosuppressive drugs in North America.

According to the data provided by the United Network for Organ Sharing (UNOS), in 2022, the total number of organ transplant procedures performed in the USA stood at 42,887, which signified an increase of 3.7% in comparison to the number of procedures performed in 2021. Moreover, as per the same source, 25,498 kidney transplant procedures were performed in 2022, representing a 3.4% increase over 2021. Such an increase in organ transplant procedures will positively impact the demand for transplant immunosuppressive drugs in the USA, accelerating market growth.

Market Developments:

• In July 2021, the U.S. Food and Drug Administration approved Astella Inc's "PROGRAF®," which would be used in the U.S. for people undergoing lung, liver, kidney, and heart transplants. Also, in December 2020, the U.S. Senate passed immunosuppressive drug legislation to extend Medicare coverage for patients who had undergone kidney transplants. Extended Medicare would enable patients to have access to all the lifesaving medications.
• In August 2022, the India-based Concord Biotech Limited, one of the market share leaders in the development and production of specific fermentation-based APIs for immunosuppressants and oncology, filed its Draught Red Herring Prospectus (DRHP) with the markets regulator Securities and Exchange Board of India (SEBI) to raise money through an initial public offering (IPO).
• In September 2022, Strides' Cyclosporine Softgel Capsules were given USFDA clearance. With the addition of Tacrolimus capsules, Cyclosporine Softgel capsules, and Mycophenolate Mofetil tablets and capsules to its range of immunosuppressant products for the U.S. market, Strides further solidified its position in the market.
• In September 2022, Cairo in the Middle East and Africa opened an organ transplant center in collaboration with foreign businesses. This organ transplant facility includes an automated database for transplants, patients, and donors.
• In September 2022, the State Organ Tissue Transplant Organisation (SOTTO) of Karnataka received official recognition from the Indian government's central office to promote organ donation in the region. A budget of INR 84 lakh (USD 101,000) was approved for the program.

Market Segmentation:

By Type

• Induction Drugs
• Maintenance Drugs

By Transplant Type

• Tissue Transplantation
• Organ Transplantation

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• South Korea
• India
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Data
• 2.3. Validation

3. EXECUTIVE SUMMARY

• 3.1. Key Findings

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis
• 4.5. Product Pipeline

5. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Induction Drugs
• 5.3. Maintenance Drugs

6. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TRANSPLANT TYPE

• 6.1. Introduction
• 6.2. Tissue Transplantation
• 6.3. Organ Transplantation

7. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. By Type
  • 7.2.2. By Transplant Type
  • 7.2.3. By Country
  • 7.2.3.1. United States
  • 7.2.3.2. Canada
  • 7.2.3.3. Mexico
• 7.3. South America
  • 7.3.1. By Type
  • 7.3.2. By Transplant Type
  • 7.3.3. By Country
  • 7.3.3.1. Brazil
  • 7.3.3.2. Argentina
  • 7.3.3.3. Others
• 7.4. Europe
  • 7.4.1. By Type
  • 7.4.2. By Transplant Type
  • 7.4.3. By Country
  • 7.4.3.1. UK
  • 7.4.3.2. Germany
  • 7.4.3.3. France
  • 7.4.3.4. Italy
  • 7.4.3.5. Spain
  • 7.4.3.6. Others
• 7.5. Middle East and Africa (MEA)
  • 7.5.1. By Type
  • 7.5.2. By Transplant Type
  • 7.5.3. By Country
  • 7.5.3.1. Saudi Arabia
  • 7.5.3.2. UAE
  • 7.5.3.3. Others
• 7.6. Asia Pacific
  • 7.6.1. By Type
  • 7.6.2. By Transplant Type
  • 7.6.3. By Country
  • 7.6.3.1. China
  • 7.6.3.2. Japan
  • 7.6.3.3. South Korea
  • 7.6.3.4. India
  • 7.6.3.5. Indonesia
  • 7.6.3.6. Thailand
  • 7.6.3.7. Taiwan
  • 7.6.3.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Emerging Players and Market Lucrativeness
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

• 9.1. Astellas Pharma Inc.
• 9.2. Bristol-Myers Squibb Company
• 9.3. Sanofi Genzyme
• 9.4. Novartis Pharmaceuticals Corporation
• 9.5. Mylan N.V.
• 9.6. Hoffmann-La Roche Ltd